High CV risk in young people is a 'delayed' crisis

Published Date: 08 Mar 2023

Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.

Read Full News

Latest News

Early Childhood Movement Tied to Active Lifestyle Later

Three movement habits in toddlerhood — active play with parents, limited screen time, and sufficient sleep — predict a more physically active lifestyle a decade later.

Sleep, Diet, Exercise Linked to Lower Cardiovascular Risk

Mobile health devices offer potential for cardiac monitoring, but false positives and integration challenges limit their current clinical use.

Cardiac Rehab Remains Underutilized Despite Benefits

Cardiac rehabilitation after transcatheter aortic valve implantation is associated with reduced risk for unplanned rehospitalization, yet it remains underutilized.

Real-World Data Back TTVR for Older Adults With Severe TR

Transcatheter tricuspid valve replacement safely improved outcomes outside a clinical trial setting.

Interval Training Boosts Fitness in Patients With ICD

Supervised high-intensity interval training significantly improves exercise capacity and quality of life in patients with an implantable cardioverter defibrillator.

Weight-Loss Drugs Reduce Muscle More Than Expected

Losing muscle mass is not the same as losing muscle strength and function, clinicians say.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Todays Updates

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Latest News

Three movement habits in toddlerhood — active play with parents, limited screen time, and sufficient sleep — predict a more physically active lifestyle a decade later.

Mobile health devices offer potential for cardiac monitoring, but false positives and integration challenges limit their current clinical use.

Cardiac rehabilitation after transcatheter aortic valve implantation is associated with reduced risk for unplanned rehospitalization, yet it remains underutilized.

Transcatheter tricuspid valve replacement safely improved outcomes outside a clinical trial setting.

Supervised high-intensity interval training significantly improves exercise capacity and quality of life in patients with an implantable cardioverter defibrillator.

Losing muscle mass is not the same as losing muscle strength and function, clinicians say.

News All Time

AF Screening May Flag Increased HF Risk

Researchers quantify the risk for heart failure among people who screen positive for atrial fibrillation and suggest ECG could be warranted.

Unexpected Results Lead to Questions on IVUS-Guided PCI

When IVUS did not outperform angiography for guiding percutaneous interventions in two trials, the results offered more questions than answers.

Poststroke Virtual Therapy No Better Than Standard Care

Early high-dose, high-intensity virtual exploratory movement therapy is not superior to standard care for hand and arm recovery after stroke, a new phase 2 trial suggests.

Well-Known Cardiac Marker Signals Kidney Decline in Diabetes

B-type natriuretic peptide shows a graded association with decline in kidney function in individuals with diabetes, even at concentrations ≤ 18.4 pg/mL, which are conventionally considered normal.

Combining GLP-1 and SGLT2 Drugs Produce Some Benefits in T2D

A large real-world study shows lower all-cause mortality and some cardiovascular outcomes with combination therapy; other outcomes lack statistical precision.

Direct Oral Anticoagulants Linked to Fewer Brain Bleeds

The use of direct oral anticoagulants is linked to fewer intracerebral haemorrhage than the use of vitamin K antagonists, without an increase in the incidence of haemorrhage at the population level.

SGLT2 Inhibitors Linked to Lower Gout Medication Need in T2D

SGLT2 inhibitors may reduce gout flares and decrease the need for urate-lowering and acute gout medications in adults with both gout and type 2 diabetes.

Do Stabilisation Admissions Support Eating Disorder Care?

More than half of children and young people admitted for medical stabilisation of restrictive eating disorders continue recovery through outpatient care, although many require nutritional support.

AI Mammography Flags Cardiovascular Risk

AI can quantify breast arterial calcifications on routine mammograms and flag women with higher cardiovascular risk, enabling opportunistic heart disease screening.

Common Kitchen Herbs May Help Prevent Obesity

Common culinary herbs such as cress, coriander, sage, and mint may help prevent and manage obesity by reducing inflammation, improving metabolic health, and supporting gut microbiota.

Insurers Fail to Get Specific on Prior Authorization Reforms

An industry trade group says prior authorization requirements have declined by 11% after last year’s pledge, but the numbers are fuzzy.

MHRA Approves Olezarsen for Rare Lipid Disorder

The MHRA has approved olezarsen for familial chylomicronaemia syndrome, a rare disorder linked to life-threatening pancreatitis.

Long COVID May Increase Your Heart Disease Risk

Individuals with long COVID face a substantially higher risk of developing cardiovascular disease — particularly cardiac arrhythmias and coronary artery disease — than those without long COVID.

Tirzepatide Bests Semaglutide in 12-Month Real-World Study

Tirzepatide is associated with a greater mean percent body weight reduction than semaglutide in adults with obesity or overweight and one or more related complications.

BP Lower Than Target in Many With Coronary Heart Disease

Over one third of patients with coronary heart disease have blood pressure below targets recommended by European guidelines and have elevated risks for heart and kidney diseases.

Lower LDL-C Target May Improve CV Outcomes

A study finds direct evidence to support guideline changes that promote lower targets for low-density lipoprotein cholesterol.

Recommended News For You

Since 2000, the outlook for multiple myeloma has improved.

A novel blood test may enable the early identification of common, fatal cancers.

Durvalumab Wins FDA Approval in Limited-Stage SCLC

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Ketamine plus psychotherapy for "excellent" PTSD

Hereditary cancer has a rare and underreported cause.

Dissociative identity disorder: method or fact?

Recommended Articles For You

The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology 

The Latest Research on Wiskott Aldrich Syndrome  

Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program 

Revolutionizing Lung Transplantation: The Promise of Donor-Specific Blood Transfusion 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Numerous Oncologists Are Concerned About the Cost of Genomic Testing.

2.

According to new studies, some cancer patients can safely forego radiation therapy.

3.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

4.

Guidelines for cervical cancer screening and the risk of preterm birth in young women.

5.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

1.

Understanding Thrombin Time: What It Is and How It Can Help Diagnose Blood Clotting Disorders

2.

Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance

3.

Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More

4.

Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment

5.

Unveiling the Mystery Behind Lymphovascular Invasion

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

2.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

5.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot